These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 2544183

  • 1. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
    Multon E, Riou JF, LeFevre D, Ahomadegbe JC, Riou G.
    Biochem Pharmacol; 1989 Jul 01; 38(13):2077-86. PubMed ID: 2544183
    [Abstract] [Full Text] [Related]

  • 2. The in vitro involvement of topoisomerase II in the activity of aza-ellipticine analogues is not correlated with drug activity on isolated nuclei.
    Vilarem MJ, Riou JF, Multon E, Gras MP, Larsen CJ.
    Biochem Pharmacol; 1986 Jul 01; 35(13):2087-95. PubMed ID: 3015146
    [Abstract] [Full Text] [Related]

  • 3. A human small cell lung carcinoma cell line, resistant to 4'-(9-acridinylamino)-methanesulfon-m-anisidide and cross-resistant to camptothecin with a high level of topoisomerase I.
    Prost S, Riou G.
    Biochem Pharmacol; 1994 Aug 30; 48(5):975-84. PubMed ID: 8093110
    [Abstract] [Full Text] [Related]

  • 4. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC, Ashorn CL, Chan D, Zwelling LA.
    Cancer Res; 1989 Apr 15; 49(8):2052-8. PubMed ID: 2539251
    [Abstract] [Full Text] [Related]

  • 5. Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage.
    Pommier Y, Minford JK, Schwartz RE, Zwelling LA, Kohn KW.
    Biochemistry; 1985 Nov 05; 24(23):6410-6. PubMed ID: 3002440
    [Abstract] [Full Text] [Related]

  • 6. Study of molecular markers of resistance to m-AMSA in a human breast cancer cell line. Decrease of topoisomerase II and increase of both topoisomerase I and acidic glutathione S transferase.
    Lefevre D, Riou JF, Ahomadegbe JC, Zhou DY, Benard J, Riou G.
    Biochem Pharmacol; 1991 Jun 15; 41(12):1967-79. PubMed ID: 1645555
    [Abstract] [Full Text] [Related]

  • 7. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.
    Zwelling LA, Hinds M, Chan D, Mayes J, Sie KL, Parker E, Silberman L, Radcliffe A, Beran M, Blick M.
    J Biol Chem; 1989 Oct 05; 264(28):16411-20. PubMed ID: 2550442
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Stimulation of the topoisomerase II induced DNA cleavage sites in the c-myc protooncogene by antitumor drugs is associated with gene expression.
    Riou JF, Lefevre D, Riou G.
    Biochemistry; 1989 Nov 14; 28(23):9104-10. PubMed ID: 2557917
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II.
    Tewey KM, Chen GL, Nelson EM, Liu LF.
    J Biol Chem; 1984 Jul 25; 259(14):9182-7. PubMed ID: 6086625
    [Abstract] [Full Text] [Related]

  • 12. Reduced topoisomerase II activity in multidrug-resistant human non-small cell lung cancer cell lines.
    Eijdems EW, de Haas M, Timmerman AJ, Van der Schans GP, Kamst E, de Nooij J, Astaldi Ricotti GC, Borst P, Baas F.
    Br J Cancer; 1995 Jan 25; 71(1):40-7. PubMed ID: 7819046
    [Abstract] [Full Text] [Related]

  • 13. Stimulation by gamma-carboline derivatives (simplified analogues of antitumor ellipticines) of site specific DNA cleavage by calf DNA topoisomerase II.
    Fossé P, René B, Saucier JM, Nguyen CH, Bisagni E, Paoletti C.
    Biochem Pharmacol; 1990 Feb 15; 39(4):669-76. PubMed ID: 2154990
    [Abstract] [Full Text] [Related]

  • 14. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S, Kooistra AJ, de Vries EG, Mulder NH, Zijlstra JG.
    Cancer Res; 1993 Mar 01; 53(5):1064-71. PubMed ID: 8382551
    [Abstract] [Full Text] [Related]

  • 15. A unique type II topoisomerase mutant that is hypersensitive to a broad range of cleavage-inducing antitumor agents.
    O'Reilly EK, Kreuzer KN.
    Biochemistry; 2002 Jun 25; 41(25):7989-97. PubMed ID: 12069589
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [In vitro stimulation by ellipticine derivatives of DNA cleavage induced by DNA topoisomerase II: a structure-activity relationship].
    Fossé P, Charra M, Paoletti C, Saucier JM, René B.
    Bull Cancer; 1994 Mar 25; 81(3):194-202. PubMed ID: 7894127
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. DNA topoisomerase I as a site of action for 10-hydroxycamptothecin in human promyelocytic leukemia cells.
    Ling YH, Andersson BS, Nelson JA.
    Cancer Biochem Biophys; 1990 Jan 25; 11(1):23-30. PubMed ID: 2159843
    [Abstract] [Full Text] [Related]

  • 20. Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.
    Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M.
    Biochemistry; 1991 Apr 23; 30(16):4048-55. PubMed ID: 1850298
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.